TY - JOUR
T1 - Parkinson's disease and skin
AU - Niemann, Nicki
AU - Billnitzer, Andrew
AU - Jankovic, Joseph
N1 - Funding Information:
Joseph Jankovic: Dr. Jankovic has received research and/or training grants from: Adamas Pharmaceuticals, Inc; Allergan, Inc; Biotie Therapies; CHDI Foundation; Civitas/Acorda Therapeutics; Dystonia Coalition; Dystonia Medical Research Foundation; F. Hoffmann-La Roche Ltd; Huntington Study Group; Kyowa Haako Kirin Pharma, Inc; Medtronic Neuromodulation; Merz Pharmaceuticals; Michael J Fox Foundation for Parkinson Research; National Institutes of Health; Neurocrine Biosciences; NeuroDerm Ltd; Parkinson's Foundation; Nuvelution; Parkinson Study Group; Pfizer Inc; Prothena Biosciences Inc; Psyadon Pharmaceuticals, Inc; Revance Therapeutics, Inc; Sangamo BioSciences, Inc.; St. Jude Medical; Teva Pharmaceutical Industries Ltd.
Funding Information:
There is no funding for this review but the authors wish to acknowledge the support of Parkinson's Foundation for their Centers of Excellence.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2021/1
Y1 - 2021/1
N2 - Parkinson's disease is associated with a variety of dermatologic disorders and the study of skin may provide insights into pathophysiological mechanisms underlying this common neurodegenerative disorder. Skin disorders in patients with Parkinson's disease can be divided into two major groups: 1) non-iatrogenic disorders, including melanoma, seborrheic dermatitis, sweating disorders, bullous pemphigoid, and rosacea, and 2) iatrogenic disorders related either to systemic side effects of antiparkinsonian medications or to the delivery system of antiparkinsonian therapy, including primarily carbidopa/levodopa, rotigotine and other dopamine agonists, amantadine, catechol-O-methyl transferase inhibitors, subcutaneous apomorphine, levodopa/carbidopa intestinal gel, and deep brain stimulation. Recent advances in our understanding of the role of α-synuclein in peripheral tissues, including the skin, and research based on induced pluripotent stem cells derived from skin fibroblasts have made skin an important target for the study of Parkinson's disease pathogenesis, drug discovery, novel stem cell therapies, and diagnostics.
AB - Parkinson's disease is associated with a variety of dermatologic disorders and the study of skin may provide insights into pathophysiological mechanisms underlying this common neurodegenerative disorder. Skin disorders in patients with Parkinson's disease can be divided into two major groups: 1) non-iatrogenic disorders, including melanoma, seborrheic dermatitis, sweating disorders, bullous pemphigoid, and rosacea, and 2) iatrogenic disorders related either to systemic side effects of antiparkinsonian medications or to the delivery system of antiparkinsonian therapy, including primarily carbidopa/levodopa, rotigotine and other dopamine agonists, amantadine, catechol-O-methyl transferase inhibitors, subcutaneous apomorphine, levodopa/carbidopa intestinal gel, and deep brain stimulation. Recent advances in our understanding of the role of α-synuclein in peripheral tissues, including the skin, and research based on induced pluripotent stem cells derived from skin fibroblasts have made skin an important target for the study of Parkinson's disease pathogenesis, drug discovery, novel stem cell therapies, and diagnostics.
KW - Apomorphine
KW - Biopsy
KW - Bullous pemphigoid
KW - Deep brain stimulation
KW - Diagnosis
KW - Levodopa
KW - Levodopa-carbidopa intestinal gel
KW - Livedo reticularis
KW - Melanoma
KW - Nodules
KW - Parkinson's disease
KW - Rosacea
KW - Seborrheic dermatitis
KW - Skin
KW - Sweating
UR - http://www.scopus.com/inward/record.url?scp=85096877832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096877832&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2020.11.017
DO - 10.1016/j.parkreldis.2020.11.017
M3 - Review article
C2 - 33248395
AN - SCOPUS:85096877832
VL - 82
SP - 61
EP - 76
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
SN - 1353-8020
ER -